DK2235017T3 - Spiroindolinonderivater som anticancermidler - Google Patents

Spiroindolinonderivater som anticancermidler

Info

Publication number
DK2235017T3
DK2235017T3 DK08863724.4T DK08863724T DK2235017T3 DK 2235017 T3 DK2235017 T3 DK 2235017T3 DK 08863724 T DK08863724 T DK 08863724T DK 2235017 T3 DK2235017 T3 DK 2235017T3
Authority
DK
Denmark
Prior art keywords
anticancer agents
spiroindolinone derivatives
spiroindolinone
derivatives
agents
Prior art date
Application number
DK08863724.4T
Other languages
English (en)
Inventor
Li Chen
Xingchun Han
Yun He
Zhuming Zhang
Song Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2235017T3 publication Critical patent/DK2235017T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK08863724.4T 2007-12-19 2008-12-09 Spiroindolinonderivater som anticancermidler DK2235017T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1488807P 2007-12-19 2007-12-19
US10738108P 2008-10-22 2008-10-22
PCT/EP2008/067061 WO2009080488A1 (en) 2007-12-19 2008-12-09 Spiroindolinone derivatives as anticancer agents

Publications (1)

Publication Number Publication Date
DK2235017T3 true DK2235017T3 (da) 2011-10-24

Family

ID=40351961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08863724.4T DK2235017T3 (da) 2007-12-19 2008-12-09 Spiroindolinonderivater som anticancermidler

Country Status (16)

Country Link
US (1) US7776875B2 (da)
EP (1) EP2235017B1 (da)
JP (1) JP2011506524A (da)
KR (1) KR20100076075A (da)
CN (1) CN101903388A (da)
AT (1) ATE524470T1 (da)
AU (1) AU2008340473A1 (da)
BR (1) BRPI0820699A2 (da)
CA (1) CA2708312A1 (da)
DK (1) DK2235017T3 (da)
ES (1) ES2372903T3 (da)
IL (1) IL205506A0 (da)
MX (1) MX2010006332A (da)
PL (1) PL2235017T3 (da)
PT (1) PT2235017E (da)
WO (1) WO2009080488A1 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100190814A1 (en) * 2009-01-26 2010-07-29 Li Chen Spiroindolinone derivative prodrugs
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) * 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
PE20121282A1 (es) * 2009-11-12 2012-10-12 Univ Michigan Antagonistas de espiro-oxindol de mdm2
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
NZ611866A (en) 2010-11-12 2015-04-24 Univ Michigan Spiro-oxindole mdm2 antagonists
AU2012226890B2 (en) * 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
AU2012253339B2 (en) 2011-05-11 2016-03-31 Sanofi Spiro-oxindole MDM2 antagonists
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
PE20221914A1 (es) 2011-12-28 2022-12-23 Global Blood Therapeutics Inc Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
CN102838610B (zh) * 2012-08-28 2014-09-10 吕叶叶 双吲哚二氧杂双环辛二酮
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6266659B2 (ja) 2013-02-28 2018-01-24 アムジエン・インコーポレーテツド 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR101971385B1 (ko) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
CN112500338A (zh) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AU2015214182B2 (en) 2014-02-07 2020-04-30 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP3164401B1 (en) 2014-07-03 2018-12-26 Boehringer Ingelheim International GmbH New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
EP3284466A4 (en) 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
US10144739B2 (en) 2015-10-09 2018-12-04 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
MA43373A (fr) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
TW201818934A (zh) 2016-10-17 2018-06-01 日商第一三共股份有限公司 Ｍｄｍ２抑制劑與ｄｎａ甲基轉移酶抑制劑之倂用治療法
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN117069647A (zh) * 2023-07-27 2023-11-17 兰州大学 一种双官能团螺环催化剂及其合成方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1361779A (zh) * 1999-07-21 2002-07-31 阿斯特拉曾尼卡有限公司 新化合物
CA2598690C (en) * 2005-02-22 2011-11-15 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
WO2007013691A1 (ja) * 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited スピロ環化合物
US20070213341A1 (en) * 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
DE602007011902D1 (de) * 2006-03-13 2011-02-24 Hoffmann La Roche Spiroindolinon-derivate
US7495007B2 (en) * 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7784589B2 (en) * 2006-07-10 2010-08-31 Inventio Ag Elevator lift cage load measuring assembly
US7638548B2 (en) * 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8134001B2 (en) * 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives

Also Published As

Publication number Publication date
EP2235017A1 (en) 2010-10-06
KR20100076075A (ko) 2010-07-05
ES2372903T3 (es) 2012-01-27
PL2235017T3 (pl) 2012-02-29
US7776875B2 (en) 2010-08-17
IL205506A0 (en) 2010-12-30
JP2011506524A (ja) 2011-03-03
BRPI0820699A2 (pt) 2019-09-24
CA2708312A1 (en) 2009-07-02
MX2010006332A (es) 2010-07-05
AU2008340473A1 (en) 2009-07-02
ATE524470T1 (de) 2011-09-15
CN101903388A (zh) 2010-12-01
US20090163512A1 (en) 2009-06-25
WO2009080488A1 (en) 2009-07-02
EP2235017B1 (en) 2011-09-14
PT2235017E (pt) 2011-10-13

Similar Documents

Publication Publication Date Title
DK2235017T3 (da) Spiroindolinonderivater som anticancermidler
ATE519764T1 (de) Spiroindolinon-derivate
ATE495176T1 (de) Spiroindolinon-derivate
TW200801000A (en) Spiroindolinone derivatives
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
IN2012DN02487A (da)
CR9980A (es) Imidazolinas 4,4,5,5 tetrasustituidas
CR20170159A (es) Nuevos compuestos tricíclicos
HRP20120323T1 (en) Diarylhydantoin compounds
WO2008005368A3 (en) Piperazines as p2x7 antagonists
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
EA201000544A1 (ru) Производные спирогетероциклического пирролидиндиона, применимые в качестве пестицидов
MY156319A (en) Spiroheterocyclic n-oxypiperidines as pesticides
RS54386B1 (en) ANTIVIRAL UNITS
RS54485B1 (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
MX2011007886A (es) Derivado de espiroindolinona piridina.
EA201270540A1 (ru) Макроциклические ингибиторы интегразы
WO2007084728A3 (en) 2-imino-benzimidazoles
ATE528290T1 (de) Spiroindolinon-derivate
NO20084543L (no) Benzimidazolderivater
RS52381B (en) 2-METHYL-1- (PHENYLSULPHONYL) -4- (PIPERAZIN-1-IL) -1H-BENZIMIDAZOLE KAO 5-HYDROXYTRIPAMINE-6 LIGAND
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
ATE469647T1 (de) Thienoä3,2-cüpyridin-7-carbonsäure-derivate